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Abstract
Background: The Xpert® MTB/RIF assay (Xpert; Cepheid, Sunnyvale, CA, USA) is a cartridge-based nucleic acid
amplification assay for rapidly diagnosing tuberculosis and assessing antibiotic sensitivity. Although previous
evidence supports the use of Xpert for diagnosing extrapulmonary tuberculosis (EPTB) in adults, information
regarding the accuracy of Xpert for EPTB only in children is lacking. This meta-analysis was performed to assess the
accuracy of Xpert for detecting EPTB in children.
Methods: We searched the MEDLINE, EMBASE, and Cochrane Infectious Diseases Group Specialized Register from
January 1, 2010 to July 16, 2019 for studies of the diagnostic performance wherein Xpert was analyzed against
cultures or composite reference standards for < 18-year-old children with EPTB.
Results: In only pediatric studies, 8 studies including 652 samples were selected. The pooled sensitivity and
specificity of Xpert for all samples were 71% (95% CI 0.63–0.79) and 97% (95% CI 0.95–0.99), respectively. The area
under the summary receiver operating characteristic (sROC) curve was 0.89. For lymph node tissues or aspirates, the
pooled sensitivity and specificity of Xpert were 80% (95% CI 0.70–0.88) and 94% (95% CI 0.89–0.97), respectively; for
cerebrospinal fluid (CSF), these values were 42% (95% CI 0.22–0.63) and 99% (95% CI 0.95–1.00), respectively.
Conclusion: Overall, Xpert displayed high specificity but modest sensitivity across various samples for diagnosing
pediatric EPTB compared to the composite reference standard. Xpert sensitivity varied with the sampling site and
was especially lower in CSF samples. Positive Xpert results may be considered to indicate a presumptive case of
pediatric EPTB, whereas negative test results indicate that the possibility of pediatric EPTB should not be excluded.
Keywords: Extrapulmonary tuberculosis, Xpert MTB/RIF, Child, Meta-analysis
Background
Tuberculosis (TB) is a serious threat to global public
health and the leading cause of death from a single in-
fectious disease worldwide, surpassing the rates of mal-
aria and HIV/AIDS. Globally, there were an estimated
10.0 million incident cases of TB in 2018, with approxi-
mately 1 million (11%) among children < 15 years. How-
ever, the mortality rate was higher in children aged < 15
years, accounting for 14% of total deaths, which is
greater than that in incident cases, suggesting poorer ac-
cess to diagnosis and treatment [1].
Extrapulmonary tuberculosis (EPTB) refers to TB oc-
curring within a location in the body other than the
lungs (e.g., meninges, lymph nodes, pleura, abdomen,
genitourinary tract, skin, joints, and bones) [2]. EPTB is
estimated to account for 8–24% (15% of the 7.0 million
incident cases on average) of all TB infections worldwide
[1]. These numbers vary in accordance with specific risk
factors in certain regions, such as age, sex, concurrent
HIV infection, and underlying comorbidities [1, 3].
EPTB commonly occurs in children and HIV-infected
individuals [4].
To diagnose EPTB, samples should be obtained from
sites of suspected infection and cultured. The diagnosis
of pediatric EPTB remains challenging because clinical
specimens are potentially inaccessible for appropriate
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sampling and require invasive diagnostic procedures [5].
Furthermore, 8–12 weeks are required to obtain the re-
sults through culturing, thus delaying treatment [6]. Be-
cause of these diagnostic challenges among children, the
incidence of pediatric EPTB is likely underestimated [7].
The Xpert® MTB/RIF assay (Xpert; Cepheid, Sunny-
vale, CA, USA) is a cartridge-based nucleic acid amplifi-
cation assay for rapid TB diagnosis and rapid antibiotic
sensitivity analysis. Currently, Xpert is used as a rapid
assay for TB diagnosis as recommended by the World
Health Organization (WHO) [1]. Since 2013, Xpert has
also been recommended for diagnosing TB meningitis
and TB lymphadenitis in children [8]. Several systematic
reviews have been conducted to determine the diagnos-
tic accuracy of Xpert for EPTB in both pediatric and
adult populations; however, no studies have specifically
evaluated for children [5, 9–16]. Therefore, data regard-
ing the accuracy of Xpert exclusively among children are
unavailable. We conducted a systematic review and
meta-analysis to assess the diagnostic accuracy of Xpert
for detecting EPTB among children.
Methods
Data sources and search strategies
We searched the MEDLINE, EMBASE, and Cochrane
Infectious Diseases Group Specialized Register. Our last
search was carried out on July 16, 2019. Furthermore,
we manually reviewed the bibliographies of the included
articles. The primary search terms were “Xpert,” “Gen-
eXpert,” “Cepheid,” “MTB/RIF,” and “Tuberculosis.” The
search methodology applied for each database is shown
in Additional file 1. The bibliography was screened for
full-length research articles in all languages. Moreover,
we reviewed the full-text to select articles describing the
exclusive analysis of pediatric EPTB.
Eligibility criteria
The following inclusion criteria were used: (1) studies
using Xpert as a diagnostic tool for detecting EPTB
compared to a reference standard in each study, with all
non-respiratory samples (i.e., lymph node aspirate or tis-
sue, CSF, pleural fluid, etc.); (2) studies evaluating the
diagnostic performance of Xpert; and (3) studies provid-
ing pediatric (0–18 years) data. Studies were included re-
gardless of HIV infection status.
We excluded reviews, letters, editorials, expert opin-
ions, animal experiments, and studies that only pre-
sented an abstract. Studies that did not include separate
pediatric data were also excluded. We attempted to in-
clude all types of EPTB samples; however, studies
reporting the use of gastric lavage samples were ex-
cluded because they were intended to diagnose pulmon-
ary TB. Studies including samples from fewer than five
patients and studies with no or insufficient data to
construct a 2 × 2 contingency table to determine sensi-
tivity and specificity were also excluded. If data were ob-
tained in more than one article from the same author,
the article with the most data was selected.
Study selection
Two review authors (YS Seo and JK Ahn) independently
assessed the titles and abstracts in accordance with the
inclusion and exclusion criteria, followed by a full-text
review of the selected studies. Discrepancies regarding
the inclusion of articles between the two authors were
resolved by the third author (DS Kim).
Composite reference standard (CRS)
To compare the accuracy of Xpert, mycobacterial cultur-
ing or a CRS was used as a reference standard. The CRS
was defined by the authors of each study. Because of the
paucibacillary characteristics of extrapulmonary TB, the
clinical diagnosis of TB was also included. The CRS in-
cluded histopathological, smearing, and clinical response
analysis to treatment with anti-TB therapy along with
culturing.
Quality assessment
Qualitative assessment was performed using the Quality
Assessment of Diagnostic Accuracy Studies-2 (QUA-
DAS-2) tool [17]. All eligible studies were evaluated
based on four domains: patient selection, index test, ref-
erence standard, and flow and timing. Each domain was
assessed in terms of the risk of bias, and the first three
domains were assessed in terms of concerns regarding
applicability.
Statistical analysis
We determined the sensitivity and specificity of Xpert
with 95% confidence intervals compared to culturing or
the CRS. To assess the heterogeneity among studies, the
chi-square test was performed. Heterogeneity was de-
fined as a p-value of < 0.10. In case of heterogeneity, dif-
ferent thresholds were considered to influence sensitivity
and specificity. To assess the presence of a threshold ef-
fect, Spearman’s ρ correlation analysis was performed
with ρ > 0.6 indicating a threshold effect. The sensitiv-
ities and specificities of Xpert in each study were deter-
mined and subjected to meta-analysis with a bivariate
random-effects model. We plotted the summary receiver
operating characteristic (sROC) curve with this model.
R-package mada (version 3.5.1.) was used to generate
forest plots and an ROC curve.
Results
Identified studies
Figure 1 shows the protocol for the screening of articles.
Of the 2225 articles obtained from MEDLINE (n = 844),
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EMBASE (n = 1180), and Cochrane (n = 201), 670 dupli-
cates were excluded. After screening the titles, 1291
studies were excluded. After screening the abstracts, 162
studies were excluded for the following reasons: 139
studies did not fulfill the inclusion criteria and 23 studies
were excluded because they were review studies, meta-
analysis studies, or case reports. After reviewing the full-
text of the remaining 102 studies, 94 studies were
excluded for the following reasons: 14 studies included
only abstracts, 6 studies did not contain EPTB samples,
11 studies had inadequate study protocols, and 63 stud-
ies did not separate pediatric data. Finally, we identified
8 studies that included 652 samples.
Study characteristics
Table 1 summarizes the characteristics of the included
studies. Five studies were conducted in Africa [18–22], 1
study in India [23], 1 study in South Korea [24], and 1 in
Italy [25]. Two studies were retrospective [24, 25] and
the remaining 6 were prospective [18–23]. All articles
were written in English. Sample numbers varied in ac-
cordance with the studies. In total, 277 lymph nodes,
218 CSF samples, 20 pleural fluid samples, and 137 mus-
culoskeletal samples were reviewed.
Quality assessment
Quality assessment was performed using QUADAS-2, as
summarized in Fig. 2. In the patient selection domain,
one study reported a high risk of bias, wherein patients
were selected through convenience [18]. Other studies
reported a low risk of bias. Regarding applicability, one
study [18] had low concern because patients were
assessed in a local hospital; another study [20] revealed
high concern because only inpatients were evaluated at a
tertiary-care center [18, 20]. Other studies reported un-
clear concern because of a lack of enough information
regarding the clinical setting [19, 21–25]. For the index
test and reference standard, the included studies gener-
ally had a low risk of bias and low applicability concerns.
Meta-analysis for diagnostic accuracy of Xpert
The 8 studies were evaluated as described above (Fig. 3).
Regardless of the sample type, the pooled sensitivity and
specificity of all samples were 71% (95% CI 0.63–0.79)
and 97% (95% CI 0.95–0.99), respectively. The area
under the ROC curve was 0.89 (Fig. 4). High heterogen-
eity was confirmed through chi-square analysis for both
sensitivity and specificity. However, it was difficult to as-
sign statistical significance to the data because of the
heterogeneity among sample types. Therefore, each sam-
ple was divided into subgroups.
Detection of lymph node TB
Six studies used Xpert to analyze lymph node samples
obtained by fine-needle aspiration biopsy (FNAB) or
lymph node biopsy rather than a CRS [18, 19, 22–25].
The pooled sensitivity and specificity of the lymph node
samples were 80% (95% CI 0.70–0.88) and 94% (95% CI
0.89–0.97), respectively. The area under the ROC curve
was 0.92. High heterogeneity was confirmed using the
chi-square test for specificity.
Fig. 1 Flow diagram showing the protocol for study selection. EPTB, extrapulmonary tuberculosis
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Fig. 2 Quality assessment based on Quality Assessment of the Diagnostic Accuracy Studies-2 (QUADAS-2) guidelines. Graphical representation of
the risk of bias and applicability concerns
Fig. 3 Forest plot of the sensitivity and specificity of Xpert in diagnosing extrapulmonary tuberculosis in comparison with a composite reference
standard in accordance with the study and specimen type. TP, true-positive; FP, false-positive; FN, false-negative; TN, true-negative
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Detection of TB meningitis
Five studies used Xpert to analyze CSF samples rather
than a CRS [21–25]. The pooled sensitivity and specifi-
city of the CSF samples were 42% (95% CI 0.22–0.63)
and 99% (95% CI 0.95–1.00), respectively. The area
under the ROC curve was 0.57. High heterogeneity was
confirmed through chi-square analysis for specificity.
Comparison with other published meta-analyses
Nine meta-analyses have been performed to assess the ac-
curacy of Xpert for detecting EPTB (Table 2) [5, 9–16].
These reviews evaluated data from both children and
adult populations; however, no studies analyzed children
alone. In these analyses, the diagnostic accuracy of Xpert
in lymph node samples showed sensitivities ranging from
83 to 96% and specificities ranging from 86 to 94% (80.2
and 94.0% in this study) [5, 10, 12, 13, 16]. In CSF sam-
ples, the sensitivities ranged from 69 to 85% and specific-
ities ranged from 97 to 100% (41.7 and 98.7% in this
study) [5, 10, 12, 13]. In the pleural fluid samples, the sen-
sitivities ranged from 34 to 51.4% and specificities ranged
from 98 to 99% [5, 10, 12–14]. In bone or joint tissue
specimens, sensitivities and specificities ranged from 84 to
91.8% and 82 to 98%, respectively [10, 15]. In bone or joint
pus specimens, the sensitivity was 82% and specificity was
99% [15]. In the joint fluid specimens, sensitivity and
specificity were 97.2% and from 90.2%, respectively [10].
However, in this study, meta-analysis of pleural TB and
bone or joint TB could not be performed because of the
small number of studies.
Discussion
The present study summarizes the overall performance
of Xpert for diagnosing pediatric EPTB based on the
currently available literature. Although previous system-
atic reviews analyzed data from both children and adult
populations, no studies have reported distinct data for
children [5, 9–16]. This study shows that Xpert has high
specificity in pediatric EPTB, although its sensitivity is
relatively lower and highly variable among specimen
types.
In a recent meta-analysis reporting data primarily
about adults, the pooled sensitivity varied among differ-
ent types of specimens (83.1% in lymph node aspirates,
71.1% in CSF, and 94.6% in bone or joint tissue). How-
ever, the pooled specificity was relatively high between
sample types (86% in lymph node aspirates, 98% in CSF,
and 85.3% in bone or joint tissue) [10]. These data agree
with the present results in that Xpert showed high speci-
ficity among various specimens in our study. Further-
more, the pooled sensitivity varied among the different
types of specimens in this study. Overall, however, the
Fig. 4 Hierarchical summary receiver operating characteristic (HSROC) curve of the diagnostic accuracy of Xpert® MTB/RIF assay (Xpert) for
extrapulmonary tuberculosis (EPTB). Summary points of the sensitivity and specificity, HSROC curve, and 95% confidence intervals. The area under
the curve of the HSROC for Xpert was 0.89
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sensitivity was lower among children than among adults,
particularly in CSF samples (42% vs. 71%) [10]. In the
case of musculoskeletal TB and pleural TB, the data
were insufficient to carry out meta-analysis to determine
the diagnostic accuracy of Xpert in pediatric popula-
tions, as two studies of musculoskeletal TB used differ-
ent sample types (tissue vs. fluid), and only one study
used pleural TB samples [20, 24]. However, these studies
also displayed lower sensitivity in children than in adults,
likely because the sample volume that can be collected
from children is relatively lower than that from adults
and because of the paucibacillary nature of EPTB in the
former [21, 23, 26]. For CSF samples, a high sample vol-
ume was shown to increase the sensitivity of Xpert [27].
The total number of TB bacilli in the test sample plays
an important role in the sensitivity of Xpert [27, 28], in-
dicating that the sensitivity of Xpert in liquid samples
may be lower than expected.
Since 2013, the WHO has recommended Xpert rather
than conventional tests for the diagnosis of TB meningi-
tis and TB lymphadenitis in children. As per the 2013
WHO data, the pooled sensitivity and specificity of
lymph node TB in children were 86% (95% CI 0.65–
0.96) and 81% (95% CI 0.54––0.93), respectively. In the
case of TB meningitis, the pooled specificity was 95%
(95% CI 0.81–0.99) and sensitivity could not be deter-
mined because of insufficient data [8]. To our know-
ledge, this is the first meta-analysis to evaluate the
sensitivity of Xpert for TB meningitis only in pediatric
populations. Our results suggest that negative Xpert re-
sults in children should be interpreted with caution with
respect to ruling out pediatric TB meningitis. However,
because TB meningitis is potentially lethal in children,
the rapidity of Xpert explains why it should be used as
an initial diagnostic test for TB meningitis despite its
low sensitivity.
Recently, the next-generation Xpert MTB/RIF assay,
Xpert MTB/RIF Ultra assay (Cepheid) (ULTRA), was de-
veloped; its limit of detection was enhanced by ~ 8-fold
compared to the previous Xpert MTB/RIF assay and it
includes a larger chamber and additional molecular tar-
gets [29]. In 2017, the WHO recommended the use of
ULTRA as a replacement for Xpert MTB/RIF in all set-
tings [30]. A single study of TB meningitis conducted in
Uganda assessed the diagnostic accuracy of Xpert and
ULTRA compared to CRS based on a positive CSF cul-
ture, Xpert, or ULTRA results. The sensitivity of detec-
tion of MTB for CSF was 95% for ULTRA (21 of 22)
relative to 45% for Xpert MTB/RIF (10 of 22) [28].
ULTRA is expected to have higher sensitivity for EPTB.
However, as discussed herein, pediatric EPTB samples
showed lower sensitivity than adult samples. ULTRA
would be helpful for the paucibacillary population, par-
ticularly in terms of diagnostic sensitivity. However,
considering that the sensitivity of the previous version of
Xpert is low in children and yielded different values
among samples, further studies are required to deter-
mine the reliability of the negative results.
EPTB is common in children but difficult to diagnose
because the sampling methods are invasive. A point-of-
care ultrasound (POCUS) protocol (focused assessment
with sonography for HIV-associated TB, FASH) is a
noninvasive diagnostic tool developed to improve the
diagnosis of EPTB in HIV-infected adults [31]. Although
few studies have been conducted in children, POCUS
has been evaluated for the diagnosis of pediatric EPTB,
with some studies showing meaningful results in chil-
dren [32]. A combination of various diagnostic methods
such as Xpert and POCUS may improve the accuracy of
diagnosing pediatric EPTB.
The present meta-analysis revealed high heterogeneity
in patients with TB lymphadenitis and meningitis. Al-
though the population was limited to those of the
pediatric age and the samples were divided into sub-
groups, differences in the processing methods of samples
and the small sample size may have resulted in high
heterogeneity.
Conclusion
In diagnosing pediatric EPTB, Xpert displayed high spe-
cificity regardless of the specimen type, but exhibited
modest sensitivity, which varied among specimen types.
Particularly, in CSF samples, Xpert displayed the lowest
sensitivity compared to the CRS. Although positive
Xpert results can be considered to indicate presumptive
EPTB in children, EPTB cannot be ruled out based on
negative test results. Future clinical trials are required to
expand the evidence for using Xpert to diagnose
pediatric EPTB with different forms of extrapulmonary
specimens in various clinical settings.
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